Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Immunol Res. 2019 Sep;7(9):1390-1395. doi: 10.1158/2326-6066.CIR-18-0605. Epub 2019 Jul 9.
In hepatocellular carcinoma (HCC), surgical resection is associated with high recurrence rate, and no effective adjuvant therapy currently exists. We initiated a pilot randomized trial of perioperative immunotherapy with nivolumab and ipilimumab for resectable HCC. Here, we provide an illustrative report of a case that achieved a complete response and report immunologic correlates of this complete pathologic response to perioperative immunotherapy. Clinical response was correlated with an increase in CD8 T-cell infiltration, with an increase in two effector T-cell clusters. This study is ongoing, and the final results may contribute to a paradigm shift in the perioperative treatment of HCC, leading to the incorporation of immunotherapy in the curative setting.
在肝细胞癌 (HCC) 中，手术切除与高复发率相关，目前尚无有效的辅助治疗方法。我们启动了一项纳武单抗和伊匹单抗用于可切除 HCC 的围手术期免疫治疗的试点随机试验。在这里，我们提供了一个完全缓解的病例说明报告，并报告了这种完全病理缓解对围手术期免疫治疗的免疫相关性。临床反应与 CD8 T 细胞浸润的增加相关，与两个效应 T 细胞簇的增加相关。该研究正在进行中，最终结果可能会促使 HCC 围手术期治疗范式发生转变，从而将免疫治疗纳入根治性治疗。
